Table 2 Secondary outcomes in the transplanted versus control patient cohort

From: The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson’s disease

Secondary outcome

Control

Transplant

Timed motor tasks, OFF (min)

−0.84 (11.8)

1.41 (16.3)

Timed motor tasks, ON (min)

3.87 (12.8)

−8.41 (20.7)

Dyskinesias, OFF (present/not present)

0/12a

3/8

Dyskinesias, ON (present/not present)

6/10

5/6

l-DOPA equivalent daily dose (mg)

306 (332)

15.6 (237)

Number of patients on l-DOPA therapy

15/0

11/0

Patient % reported OFF time

4.23 (12.0)

−7.75 (13.1)

Quality of life (PDQ-39)

10.1 (11.8)

3.6 (5.3)

[18F]FDOPA PET

Planned 36-month scanning could not be performed

 
  1. Values represent mean (s.d.) change from baseline to 36 months or counts (no/yes) at 36 months for dyskinesias with l-DOPA therapy (ON/OFF).
  2. aSome of the control individuals did not want to come off medication, which is why this number is 12 and not 16.
Back to article page